Amgen Inc logo

Amgen Inc

21
6
NAS:AMGN (USA)   Ordinary Shares
$ 289.45 +4.2696 (+1.5%) 03:57 PM EST
23.17
P/B:
24.87
Market Cap:
$ 155.12B
Enterprise V:
$ 206.50B
Volume:
1.93M
Avg Vol (2M):
2.89M
Also Trade In:
Volume:
1.93M
Avg Vol (2M):
2.89M
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Amgen Inc ( ) from 1990 to Feb 23 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Amgen stock (AMGN) PE ratio as of Feb 23 2024 is 23.17. More Details

Amgen Inc (AMGN) PE Ratio (TTM) Chart

To

Amgen Inc (AMGN) PE Ratio (TTM) Historical Data

Total 1236
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Amgen PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-02-23 23.2 2023-12-18 19.6
2024-02-22 22.8 2023-12-15 19.6
2024-02-21 22.7 2023-12-14 19.6
2024-02-20 22.7 2023-12-13 20.0
2024-02-16 22.7 2023-12-12 19.5
2024-02-15 23.1 2023-12-11 19.3
2024-02-14 23.2 2023-12-08 19.1
2024-02-13 23.3 2023-12-07 19.3
2024-02-12 23.6 2023-12-06 19.1
2024-02-09 23.3 2023-12-05 19.3
2024-02-08 23.6 2023-12-04 19.4
2024-02-07 23.7 2023-12-01 19.4
2024-02-06 25.3 2023-11-30 19.2
2024-02-05 25.8 2023-11-29 18.9
2024-02-02 25.9 2023-11-28 18.9
2024-02-01 26.0 2023-11-27 18.8
2024-01-31 25.2 2023-11-24 18.9
2024-01-30 25.2 2023-11-22 18.8
2024-01-29 25.1 2023-11-21 18.7
2024-01-26 25.0 2023-11-20 18.9
2024-01-25 24.8 2023-11-17 18.9
2024-01-24 24.5 2023-11-16 19.1
2024-01-23 24.8 2023-11-15 19.4
2024-01-22 24.8 2023-11-14 19.2
2024-01-19 24.6 2023-11-13 18.9
2024-01-18 24.4 2023-11-10 19.0
2024-01-17 24.4 2023-11-09 18.8
2024-01-16 24.3 2023-11-08 19.4
2024-01-12 24.5 2023-11-07 19.3
2024-01-11 24.3 2023-11-06 19.4
2024-01-10 24.4 2023-11-03 19.2
2024-01-09 24.6 2023-11-02 18.9
2024-01-08 24.9 2023-11-01 18.5
2024-01-05 24.3 2023-10-31 18.2
2024-01-04 24.3 2023-10-30 18.7
2024-01-03 24.1 2023-10-27 18.6
2024-01-02 23.8 2023-10-26 19.2
2023-12-29 23.1 2023-10-25 19.3
2023-12-28 23.1 2023-10-24 19.6
2023-12-27 20.4 2023-10-23 19.4
2023-12-26 20.2 2023-10-20 19.8
2023-12-22 20.2 2023-10-19 19.9
2023-12-21 19.9 2023-10-18 20.1
2023-12-20 19.6 2023-10-17 20.2
2023-12-19 19.8 2023-10-16 20.4

Amgen Inc (AMGN) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.